loading page

Towards a “druggable” epitranscriptome: Compounds that target RNA modifications in cancer
  • Maria Berdasco,
  • Manel Esteller
Maria Berdasco
Josep Carreras Leukaemia Research Institute (IJC)

Corresponding Author:[email protected]

Author Profile
Manel Esteller
Josep Carreras Leukaemia Research Institute (IJC)
Author Profile


Epitranscriptomics is an exciting emerging area that studies biochemical modifications of RNA. The field is boosted by the technical efforts of the last decade to characterize and quantify RNA modifications which have led to a map of post-transcripcional RNA marks in normal cell fate and develoment. However, the scientific interest has been fueled by the discovery of aberrant epitranscriptomes associated with human diseases, mainly cancer. The challenge is now to see whether epitrancriptomics offers a tunable mechanims to be targeted by small- molecule intervention. In this review, we will describe the principal RNA modifications (with a focus on mRNA), summarize the latest scientific evidences of their dysregulation in cancer and provide an overview of the state-of-the-art drug discovery to target the epitranscriptome. Finally, we will discuss the principal challenges in the field of chemical biology and drug development to increase the potential of targeted-RNA for clinical benefit.
09 Nov 2020Submitted to British Journal of Pharmacology
09 Nov 2020Submission Checks Completed
09 Nov 2020Assigned to Editor
11 Nov 2020Reviewer(s) Assigned
03 Dec 2020Review(s) Completed, Editorial Evaluation Pending
03 Dec 2020Editorial Decision: Revise Minor
27 May 20211st Revision Received
31 May 2021Submission Checks Completed
31 May 2021Assigned to Editor
06 Jun 2021Review(s) Completed, Editorial Evaluation Pending
10 Jun 2021Editorial Decision: Accept
27 Jul 2021Published in British Journal of Pharmacology. 10.1111/bph.15604